Endoscopic intestinal bypass creation by using self-assembling magnets in a porcine model - 31/05/16
Abstract |
Background and Aims |
A purely endoluminal method of GI bypass would be desirable for the treatment of obstruction, obesity, or metabolic syndrome. We have developed a technology based on miniature self-assembling magnets that create large-caliber anastomoses (Incisionless Anastomosis System [IAS]). The aim of this study was to evaluate procedural characteristics of IAS deployment and long-term anastomotic integrity and patency.
Methods |
We performed a 3-month survival study of Yorkshire pigs (5 interventions, 3 controls). Intervention pigs underwent simultaneous enteroscopy/colonoscopy performed with the animals under intravenous sedation. The IAS magnets were deployed and coupled with reciprocal magnets under fluoroscopy. Every 3 to 6 days pigs underwent endoscopy until jejunocolonic anastomosis (dual-path bypass) creation and magnet expulsion. Necropsies and histological evaluation were performed. The primary endpoints were technical success; secondary endpoints of anastomosis integrity, patency, and histological characteristics were weight trends.
Results |
Under intravenous sedation, endoscopic bypass creation by using IAS magnets was successfully performed in 5 of 5 pigs (100%). Given porcine anatomy, the easiest dual-path bypass to create was between the proximal jejunum and colon. The mean procedure time was 14.7 minutes. Patent, leak-free anastomoses formed by day 4. All IAS magnets were expelled by day 12. All anastomoses were fully patent at 3 months with a mean diameter of 3.5 cm. The mean 3-month weight was 45 kg in bypass pigs and 78 kg in controls (P = .01). At necropsy, adhesions were absent. Histology showed full re-epithelialization across the anastomosis without fibrosis or inflammation.
Conclusion |
Large-caliber, leak-free, foreign body–free endoscopic intestinal bypass by using IAS magnets can be safely and rapidly performed in the porcine by model using only intravenous sedation.
Il testo completo di questo articolo è disponibile in PDF.Abbreviation : IAS
Mappa
| DISCLOSURE: Dr Ryou disclosed that he is a founder of and consultant to, receives royalties from, and has equity in GI Windows and is a consultant to and received honoraria from Covidien and Medtronic. Dr Thompson is a founder of and consultant to, receives royalties from, and has equity in GI Windows; receives research support from and is a consultant to Olympus and Bard; is a consultant to Boston Scientific; is a consultant to, receives royalties from, and has stock in Beacon Endoscopic/Covidien. Dr Agoston disclosed no financial relationships relevant to this publication. |
Vol 83 - N° 4
P. 821-825 - aprile 2016 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?
